Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex to initiate Phase III study of hepatitis drug
The trial will be conducted in the US and EU and will enroll approximately 650 genotype 1 hepatitis C virus (HCV) patients who failed prior treatment with pegylated-interferon
The trial will be conducted in the US and EU and will enroll approximately 650 genotype 1 hepatitis C virus (HCV) patients who failed prior treatment with pegylated-interferon
In this newly created position, Dr Tapolsky will be responsible for the leadership of all preclinical and clinical development activities. Prior to joining Advanced Cancer Therapeutics, Dr Tapolsky
Cellumen is focused on decreasing the drug attrition rate due to toxicity. The company’s CellCiphr CSB toxicity profiling services can identify toxic compounds in late primary screening through
Preclinical testing has indicated that these insulin receptor activators, as single agents, lower glucose levels in models of diabetes. The compounds are active in the presence of sub-maximal
Melior is using theraTRACE to both build an internal pipeline of development candidates as well as sharing this capability with pharmaceutical and biotechnology company partners. Andrew Reaume, president
Bayhealth Medical Center is the first healthcare facility in Delaware to become a member of the University of Pennsylvania Cancer Network. The cancer affiliation with Bayhealth is University
Under the terms of the agreement, Lupin Pharmaceuticals, USA, will use its 50 person sales force to promote the product to pediatricians. This agreement with Forest Laboratories is
The law also calls upon the state to develop an industry code of conduct and impose fines of $5,000 for every violation. Also, under the new law, all
According to senators Baucus and Conrad who, respectively, chair the Senate finance and budget committees, the institute created by the bill would be a private-entity, non-profit organization responsible
Under the terms of the collaboration, Bristol-Myers Squibb would pay PDL BioPharma an upfront cash payment of $30 million for the development and marketing rights to elotuzumab and